Naslov
2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina

Autori
Bešlija, Semir ; Gojković, Zdenka ; Cerić, Timur ; Mekić Abazović, Alma ; Marijanović, Inga ; Vranić, Semir ; Mustedanagić–Mujanović, Jasminka ; Skenderi, Faruk ; Rakita, Ivanka ; Guzijan, Aleksandar ; Koprić, Dijana ; Humačkić, Alen ; Trokić, Danijela ; Alidžanović, Jasmina ; Efendić, Alma ; Šišić, Ibrahim ; Drljević, Harun ; Bešlagić, Vanesa ; Babić, Božana ; Pašić, Azra ; Ramić, Anela ; Mikić, Dijana ; Guzin, Zlatko ; Karan, Dragana ; Buhovac, Teo ; Miletić, Dragana ; Šečić, Senad ; Đozić Šahmić, Azra ; Mujbegović, Lejla ; Kubura, Alisa ; Burina, Mensura ; Lalović, Nenad ; Dukić, Nikolina ; Vladičić Mašić, Jelena ; Ćuk, Mirjana ; Stanušić, Rajna

Izvornik
Bosnian journal of basic medical sciences (1512-8601) 21 (2020), 2; 120-135

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni

Ključne riječi
breast cancer ; her2 ; trastuzumab ; guidelines
(breast cancer ; her2 ; trastuzumab ; gudelines)

Sažetak
The HERe2Cure project, which involved a group of breast cancer experts, members of multidisciplinary tumor boards from healthcare institutions in Bosnia and Herzegovina, was initiated with the aim of defining an optimal approach to the diagnosis and treatment of HER2 positive breast cancer. After individual multidisciplinary consensus meetings were held in all oncology centers in Bosnia and Herzegovina, a final consensus meeting was held in order to reconcile the final conclusions discussed in individual meetings. Guidelines were adopted by consensus, based on the presentations and suggestions of experts, which were first discussed in a panel discussion and then agreed electronically between all the authors mentioned. The conclusions of the panel discussion represent the consensus of experts in the field of breast cancer diagnosis and treatment in Bosnia and Herzegovina. The objectives of the guidelines include the standardization, harmonization and optimization of the procedures for the diagnosis, treatment and monitoring of patients with HER2- positive breast cancer, all of which should lead to an improvement in the quality of health care of mentioned patients. The initial treatment plan for patients with HER2-positive breast cancer must be made by a multidisciplinary tumor board comprised of at least: a medical oncologist, a pathologist, a radiologist, a surgeon, and a radiation oncologist/radiotherapist.

Izvorni jezik
Engleski

Znanstvena područja
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)

POVEZANOST RADA